18273716. METHODS FOR TREATING AND AMELIORATING CANCER simplified abstract (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA)
Contents
- 1 METHODS FOR TREATING AND AMELIORATING CANCER
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 METHODS FOR TREATING AND AMELIORATING CANCER - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 How does the combination of imetelstat and second drugs affect cancer stem cell populations in vivo?
- 1.11 What are the potential side effects of using imetelstat in combination with other drugs for cancer treatment?
- 1.12 Original Abstract Submitted
METHODS FOR TREATING AND AMELIORATING CANCER
Organization Name
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor(s)
Catriona Jamieson of San Diego CA (US)
Wenxue Ma of San Diego CA (US)
METHODS FOR TREATING AND AMELIORATING CANCER - A simplified explanation of the abstract
This abstract first appeared for US patent application 18273716 titled 'METHODS FOR TREATING AND AMELIORATING CANCER
Simplified Explanation
The patent application describes methods for treating cancer such as acute myeloid leukemia (AML) using a pharmaceutical composition comprising imetelstat and a second drug.
- Imetelstat is used in combination with drugs such as dasatinib, ruxolitinib, fedratinib, 8-aza-adenosine, raltegravir, and/or dolutegravir for treating AML.
- The pharmaceutical composition inhibits myeloproliferative neoplasm (MPN) or AML stem cell propagation in vivo.
- Imetelstat is also effective in inhibiting pre-leukemia stem cell transformation into leukemia stem cells (LSCs) when used in combination with second drugs like dasatinib, ruxolitinib, fedratinib, 8-aza-adenosine, raltegravir, and/or dolutegravir.
Potential Applications
The technology can be applied in the treatment of various types of cancer, particularly AML and MPN.
Problems Solved
This technology addresses the challenge of inhibiting cancer stem cell propagation and transformation, which are key factors in the progression of leukemia.
Benefits
The use of imetelstat in combination with other drugs offers a promising approach to treating AML and MPN by targeting cancer stem cells.
Potential Commercial Applications
The technology has potential commercial applications in the pharmaceutical industry for the development of novel cancer treatments.
Possible Prior Art
Previous research has explored the use of imetelstat in cancer treatment, but the specific combination with second drugs for inhibiting stem cell propagation and transformation may be novel.
Unanswered Questions
How does the combination of imetelstat and second drugs affect cancer stem cell populations in vivo?
Further research is needed to understand the mechanisms by which the combination of imetelstat and second drugs inhibits cancer stem cell propagation and transformation.
What are the potential side effects of using imetelstat in combination with other drugs for cancer treatment?
Studies are required to investigate the safety profile of the pharmaceutical composition comprising imetelstat and second drugs in cancer patients.
Original Abstract Submitted
In alternative embodiments, provided are methods for treating and ameliorating a cancer such as a leukemia such as acute myeloid leukemia (AML) comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug such as dasatinib, or ruxolitinib, fedratinib, 8-aza-adenosine, raltegravir and/or dolutegravir or any combination thereof. In alternative embodiments, provided are methods for the in vivo inhibition of myeloproliferative neoplasm (MPN) or AML stem cell propagation comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug. In alternative embodiments, provided are methods for the in vivo inhibition pre-leukemia stem cell (pre-LSC) transformation into leukemia stem cells (LSCs) comprising administration to an individual in need thereof a pharmaceutical composition comprising imetelstat, or imetelstat and second drug such as dastinib, or ruxolitinib, fedratinib, 8-aza-adenosine, raltegravir and/or dolutegravir or any combination thereof.
